TrialThe oncologist2020

The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).

Shunjun Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.